Literature DB >> 9577367

Endometrial carcinoma: immunohistochemically detected proliferation index is a prognosticator of long-term outcome.

A M Gassel1, J Backe, S Krebs, S Schön, H Caffier, H K Müller-Hermelink.   

Abstract

AIM: To test which immunohistochemically detected tumour parameters are predictive of outcome in endometrial carcinoma.
METHODS: A retrospective study of 300 patients diagnosed with endometrial carcinoma between 1980 and 1985, ensuring a follow up of at least 10 years. Paraffin wax embedded tissues from 236 patients with endometrial carcinoma were evaluated in terms of histological tumour type and grade, stage of disease, and certain immunohistochemical biological parameters. These parameters included the expression of oestrogen and progesterone receptors, the expression of p53 protein, the expression of the c-erbB-2 oncoprotein, and the expression of protease cathepsin D, together with the rate of cell proliferation.
RESULTS: Using univariate analysis, the following parameters correlated significantly with adjusted survival: histological type (p = 0.025), grade (p = 0.00003), FIGO stage (p < 0.00001), proliferation rate (p = 0.00002), oestrogen receptor expression (p = 0.007), progesterone receptor expression (p = 0.0092), and p53 expression (p = 0.00028). These parameters also correlated significantly with both disease free and overall survival. There was a weak correlation of cathepsin D expression with survival, but no correlation of c-erb B-2 expression with survival. Using multivariate analysis, only FIGO stage (p = 0.0021), histological grade (p = 0.005), and proliferation rate (p = 0.0007) remained statistically significant prognosticators of adjusted survival as well as of disease free and overall survival.
CONCLUSIONS: In addition to conventional histological parameters, the immunohistochemical determination of proliferative activity could contribute to the identification of a high risk subgroup of endometrial carcinomas. The other parameters tested were not of significant additional predictive value.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9577367      PMCID: PMC500426          DOI: 10.1136/jcp.51.1.25

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  35 in total

1.  Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study.

Authors:  W T Creasman; C P Morrow; B N Bundy; H D Homesley; J E Graham; P B Heller
Journal:  Cancer       Date:  1987-10-15       Impact factor: 6.860

2.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue].

Authors:  W Remmele; H E Stegner
Journal:  Pathologe       Date:  1987-05       Impact factor: 1.011

3.  The value of immunohistochemistry in the differential diagnosis of endometrial carcinomas.

Authors:  G Dallenbach-Hellweg; G Lang-Avérous; U Hahn
Journal:  APMIS Suppl       Date:  1991

4.  Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma.

Authors:  N W Hamel; T J Sebo; T O Wilson; G L Keeney; P C Roche; V J Suman; T C Hu; K C Podratz
Journal:  Gynecol Oncol       Date:  1996-08       Impact factor: 5.482

5.  Tumor size in endometrial cancer.

Authors:  J C Schink; A W Rademaker; D S Miller; J R Lurain
Journal:  Cancer       Date:  1991-06-01       Impact factor: 6.860

6.  Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor.

Authors:  E M Segreti; D B Novotny; J T Soper; D G Mutch; W T Creasman; K S McCarty
Journal:  Obstet Gynecol       Date:  1989-05       Impact factor: 7.661

7.  Overexpression and mutation of p53 in endometrial carcinoma.

Authors:  M F Kohler; A Berchuck; A M Davidoff; P A Humphrey; R K Dodge; J D Iglehart; J T Soper; D L Clarke-Pearson; R C Bast; J R Marks
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

8.  Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium.

Authors:  R M Bigsby; A X Li; J Bomalaski; F B Stehman; K Y Look; G P Sutton
Journal:  Obstet Gynecol       Date:  1992-01       Impact factor: 7.661

9.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.

Authors:  P L Porter; A M Gown; S G Kramp; M D Coltrera
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

10.  Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease.

Authors:  W M Christopherson; P J Connelly; R C Alberhasky
Journal:  Cancer       Date:  1983-05-01       Impact factor: 6.860

View more
  4 in total

Review 1.  Prognostic biomarkers in endometrial and ovarian carcinoma.

Authors:  Xavier Matias-Guiu; Ben Davidson
Journal:  Virchows Arch       Date:  2014-02-07       Impact factor: 4.064

2.  Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.

Authors:  E Jason Gates; Lawrence Hirschfield; Roland P Matthews; O W Stephanie Yap
Journal:  J Natl Med Assoc       Date:  2006-11       Impact factor: 1.798

3.  Minichromosome maintenance complex component 6 (MCM6) expression correlates with histological grade and survival in endometrioid endometrial adenocarcinoma.

Authors:  Judicaël Hotton; Mikaël Agopiantz; Agnès Leroux; Claire Charra-Brunaud; Béatrice Marie; Hélène Busby-Venner; Olivier Morel; Jean-Louis Guéant; Jean-Michel Vignaud; Shyue-Fang Battaglia-Hsu; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-12-14       Impact factor: 4.064

4.  P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome.

Authors:  Ryszard Jeczen; Danuta Skomra; Marek Cybulski; Regine Schneider-Stock; Wiktor Szewczuk; Albert Roessner; Tomasz Rechberger; Andrzej Semczuk
Journal:  Clin Exp Metastasis       Date:  2007-08-02       Impact factor: 4.510

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.